The pergonal market research report is one of a series of new reports that provides pergonal market statistics, including pergonal industry global market size, regional shares, competitors with a pergonal market share, detailed pergonal market segments, market trends, and opportunities, and any further data you may need to thrive in the pergonal industry. This pergonal market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can raise demand for assisted reproductive technologies (art), increasing awareness and acceptance of fertility treatments, advancements in reproductive medicine, expanding healthcare infrastructure, rising maternal age, and delayed childbearing. Major trends in the growth of personalized fertility treatment plans, integration of advanced diagnostic tools with fertility therapies, increasing use of combination hormone therapies, adoption of telemedicine for fertility consultations, and focus on patient-centric care in reproductive health.
The growing prevalence of infertility is expected to drive the expansion of the Pergonal market. Infertility is defined as the inability to conceive or maintain a pregnancy to full term, and it is becoming more common due to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the rising rates of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergonal aids in infertility treatment by stimulating ovulation through its combination of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which encourages egg production in women with ovulatory issues. According to the World Health Organization, approximately 17.5% of adults globally, or one in six individuals, are affected by infertility. This rising prevalence is contributing to the growth of the Pergonal market.
The increasing trend toward later-age family planning is also expected to boost the growth of the Pergonal market. Later-age family planning involves delaying childbirth for personal, financial, or career reasons, with the use of contraception and fertility preservation methods to manage pregnancy timing. This shift is influenced by factors such as greater career focus, higher levels of education, financial considerations, and improved access to reproductive technologies. Pergonal plays a key role in supporting women who delay childbearing by stimulating ovary function and improving the chances of conception. According to the United States Census Bureau, over a 30-year period, fertility rates among women aged 20-24 decreased by 43%, while those for women aged 35-39 increased by 67%. This trend towards later-age family planning is fueling the demand for Pergonal.
The growth of healthcare expenditure is expected to drive the Pergonal market as well. Increasing healthcare spending is driven by the rising prevalence of chronic diseases, advancements in medical technologies, aging populations, and the growing demand for quality healthcare services. This increase in healthcare expenditure improves access to advanced fertility treatments and makes assisted reproductive technologies more affordable for patients. For example, in the UK, healthcare spending grew by 5.6% from 2022 to 2023, reaching approximately $317.63 billion (£292 billion). The rise in healthcare expenditure will contribute significantly to the growth of the Pergonal market.
The countries covered in the pergonal market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pergonal is a biologic drug that contains a combination of human menopausal gonadotropin (hMG), which includes both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is primarily used in fertility treatments to stimulate ovulation in women who struggle with conceiving due to anovulation. Derived from the urine of postmenopausal women, Pergonal helps stimulate the ovaries to produce eggs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Pergonal include infertility treatment, hypogonadism, and ovarian stimulation. Infertility refers to the inability of a couple to conceive after trying for at least one year without using contraception. Pergonal is distributed through pharmacies and online platforms, and it is used by a range of end users, including hospitals, fertility clinics, and home care settings.
The pergonal market consists of sales of menotropins, luteinizing hormone, and follicle-stimulating hormones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can raise demand for assisted reproductive technologies (art), increasing awareness and acceptance of fertility treatments, advancements in reproductive medicine, expanding healthcare infrastructure, rising maternal age, and delayed childbearing. Major trends in the growth of personalized fertility treatment plans, integration of advanced diagnostic tools with fertility therapies, increasing use of combination hormone therapies, adoption of telemedicine for fertility consultations, and focus on patient-centric care in reproductive health.
The growing prevalence of infertility is expected to drive the expansion of the Pergonal market. Infertility is defined as the inability to conceive or maintain a pregnancy to full term, and it is becoming more common due to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the rising rates of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergonal aids in infertility treatment by stimulating ovulation through its combination of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which encourages egg production in women with ovulatory issues. According to the World Health Organization, approximately 17.5% of adults globally, or one in six individuals, are affected by infertility. This rising prevalence is contributing to the growth of the Pergonal market.
The increasing trend toward later-age family planning is also expected to boost the growth of the Pergonal market. Later-age family planning involves delaying childbirth for personal, financial, or career reasons, with the use of contraception and fertility preservation methods to manage pregnancy timing. This shift is influenced by factors such as greater career focus, higher levels of education, financial considerations, and improved access to reproductive technologies. Pergonal plays a key role in supporting women who delay childbearing by stimulating ovary function and improving the chances of conception. According to the United States Census Bureau, over a 30-year period, fertility rates among women aged 20-24 decreased by 43%, while those for women aged 35-39 increased by 67%. This trend towards later-age family planning is fueling the demand for Pergonal.
The growth of healthcare expenditure is expected to drive the Pergonal market as well. Increasing healthcare spending is driven by the rising prevalence of chronic diseases, advancements in medical technologies, aging populations, and the growing demand for quality healthcare services. This increase in healthcare expenditure improves access to advanced fertility treatments and makes assisted reproductive technologies more affordable for patients. For example, in the UK, healthcare spending grew by 5.6% from 2022 to 2023, reaching approximately $317.63 billion (£292 billion). The rise in healthcare expenditure will contribute significantly to the growth of the Pergonal market.
The key company operating in the pergonal market is Merck KGaA
North America was the largest region in the pergonal market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pergonal report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the pergonal market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pergonal is a biologic drug that contains a combination of human menopausal gonadotropin (hMG), which includes both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is primarily used in fertility treatments to stimulate ovulation in women who struggle with conceiving due to anovulation. Derived from the urine of postmenopausal women, Pergonal helps stimulate the ovaries to produce eggs.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Pergonal include infertility treatment, hypogonadism, and ovarian stimulation. Infertility refers to the inability of a couple to conceive after trying for at least one year without using contraception. Pergonal is distributed through pharmacies and online platforms, and it is used by a range of end users, including hospitals, fertility clinics, and home care settings.
The pergonal market consists of sales of menotropins, luteinizing hormone, and follicle-stimulating hormones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pergonal Market Characteristics4. Pergonal Market Trends And Strategies5. Pergonal Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Pergonal Pricing Analysis & Forecasts30. Global Pergonal Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Pergonal Market32. Recent Developments In The Pergonal Market
3. Pergonal Market Biologic Drug Characteristics
6. Global Pergonal Growth Analysis And Strategic Analysis Framework
8. Pergonal Market Segmentation
9. Global Pergonal Epidemiology Of Clinical Indications
10. Pergonal Market Regional And Country Analysis
11. Asia-Pacific Pergonal Market
12. China Pergonal Market
13. India Pergonal Market
14. Japan Pergonal Market
15. Australia Pergonal Market
16. South Korea Pergonal Market
17. Western Europe Pergonal Market
18. UK Pergonal Market
19. Germany Pergonal Market
20. France Pergonal Market
21. Eastern Europe Pergonal Market
22. North America Pergonal Market
23. USA Pergonal Market
24. Canada Pergonal Market
25. South America Pergonal Market
26. Middle East Pergonal Market
27. Africa Pergonal Market
28. Pergonal Market Competitive Landscape And Company Profiles
29. Global Pergonal Market Pipeline Analysis
33. Pergonal Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Pergonal Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pergonal market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pergonal ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pergonal market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Infertility Treatment; Hypogonadism; Ovarian Stimulation2) By Distribution Channel: Pharmacies; Online Pharmacies
3) By End User: Hospitals; Fertility Clinics; Home Care
Key Companies Profiled: Merck KGaA
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck KGaA
